The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Eligibility
Sex
FEMALE
Min age
0 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
* Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy
Exclusion Criteria:
• Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy
Primary outcome measure(s)
Major congenital malformation (birth defect) — Annually beginning April 2022 Healthcare provider report through the registry
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.